Review pending. Every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review has not yet been carried out, and these pages are not indexed.AI-assisted source check done; independent review pending; not indexed. About the review
Dis-Chem
On this page
Company details
- Legal name
- Dis-Chem Pharmacies Limited
- Incorporated in
- South Africa
- Listing
- DCP on the A2X Markets, active · ISIN ZAE000227831 (observed 2026-10-08)
- Sector
- Not classified (our classification from the stated principal activity)
- Financial year ends
- 28 February
Overview
Year ended 28 February 2026 · summary financial statements, final status not established · source
Read with these figures
- Summary financial statements not confirmed as final. The published copy is not confirmed as the final version. The FY to 28 Feb 2026 figures come from it.
Full wording and sources
Summary financial statements for 2026: final status not established
Published by the issuer inside its Integrated Report 2026. No auditor's report on the summary is printed. The report states that the Annual Financial Statements were audited by Forvis Mazars, who issued an unmodified audit opinion, and that the Integrated Annual Report itself is not subject to separate external assurance (PDF p4). The Board approved the Integrated Annual Report for release on 29 June 2026; the statement closes with the typeset names Larry Nestadt (Independent Non-Executive Chair) and Rui Morais (CEO), with no visible signatures (PDF p5, page image).
Source: Dis-Chem Integrated Report 2026 for the financial year ended 28 February 2026 — Summary consolidated financial information (dated 2026-06-29)
2026, 2025: figures from a published summary
These columns come from the issuer's summary financial statements, not its full financial statements; the summary does not state that its source statements were audited. The summary does not state its source. (Section 'Summary consolidated financial information', pp108-114.) No auditor's report on the summary is printed; the summary section states nothing about its source or assurance (pp108-114). Elsewhere the report states: 'The AFS have been audited by Forvis Mazars, who issued an unmodified audit opinion.' and 'While the IAR itself is not subject to separate external assurance, it has been reviewed by executive management, the Audit and Risk Committee and the Board' (p4). Consolidated statement of comprehensive income (p108), statement of financial position (p109), statement of changes in equity (p110), statement of cash flows (p111), earnings per share (p112) and segmental information (pp113-114); no accounting policies or other notes. Condensed lines: section subtotals are printed above their components; no total-liabilities line; additions to property, plant and equipment and intangible assets are printed only as 'to maintain' and 'to expand' operations.
Source: Dis-Chem Integrated Report 2026 for the financial year ended 28 February 2026 — Summary consolidated financial information (dated 2026-06-29)
-
Revenue
ZAR 42.8 billion
42,825,777 ZAR thousands · p108
+9.3% vs 2025
-
Operating profit / (loss)
ZAR 1.85 billion
1,853,114 ZAR thousands · p108
−11.9% vs 2025
-
Profit / (loss) for the year
ZAR 1.04 billion
1,035,618 ZAR thousands · p108
−15.1% vs 2025
-
Total assets
ZAR 20.7 billion
20,738,283 ZAR thousands · p109
+7.7% vs 2025
-
Total equity
ZAR 5.69 billion
5,694,225 ZAR thousands · p109
+8.9% vs 2025
-
Cash from operations
ZAR 1.79 billion
1,792,711 ZAR thousands · p111
+98.2% vs 2025
Large amounts are rounded for reading (ZAR million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.
Financial statements
Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in ZAR thousands unless the row says otherwise; brackets are negative.
† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table
Column sources
- FY to 28 Feb 2026 — summary financial statements (summary), final status not established; reported for the year · source
- FY to 28 Feb 2025 — summary financial statements (summary), final status not established; comparative in the FY to 28 Feb 2026 filing · source
- 2026, 2025: figures from a published summary. These columns come from the issuer's summary financial statements, not its full financial statements; the summary does not state that its source statements were audited. The summary does not state its source. (Section 'Summary consolidated financial information', pp108-114.) No auditor's report on the summary is printed; the summary section states nothing about its source or assurance (pp108-114). Elsewhere the report states: 'The AFS have been audited by Forvis Mazars, who issued an unmodified audit opinion.' and 'While the IAR itself is not subject to separate external assurance, it has been reviewed by executive management, the Audit and Risk Committee and the Board' (p4). Consolidated statement of comprehensive income (p108), statement of financial position (p109), statement of changes in equity (p110), statement of cash flows (p111), earnings per share (p112) and segmental information (pp113-114); no accounting policies or other notes. Condensed lines: section subtotals are printed above their components; no total-liabilities line; additions to property, plant and equipment and intangible assets are printed only as 'to maintain' and 'to expand' operations.
Income statement
| Line (as printed) | FY to 28 Feb 2026Summary financial statements (summary)reported for the year | FY to 28 Feb 2025Summary financial statements (summary)comparative in FY to 28 Feb 2026 filingsource limitations |
|---|---|---|
| Revenue from contracts with customers | 42,825,777 | 39,172,347 |
| Cost of sales | (33,416,598) | (30,371,972) |
| Gross profit | 9,409,179 | 8,800,375 |
| Other income | 3,797,149 | 3,347,467 |
| Total income1 | 13,206,328 | 12,147,842 |
| Other expenses | (11,353,214) | (10,043,744) |
| Operating profit before interest and equity accounted earnings | 1,853,114 | 2,104,098 |
| Net financing costs2 | (506,568) | (490,605) |
| – Finance income | 47,498 | 30,400 |
| – Finance costs | (554,066) | (521,005) |
| Profit from associates and joint ventures | 48,179 | 20,207 |
| Profit before taxation | 1,394,725 | 1,633,700 |
| Taxation | (359,107) | (414,462) |
| Total profit for the year, net of taxation | 1,035,618 | 1,219,238 |
| – Exchange differences on translating foreign subsidiaries3 | 963 | (106) |
| Other comprehensive income for the year, net of taxation | 963 | (106) |
| Total comprehensive income for the year | 1,036,581 | 1,219,132 |
| – Non-controlling interests4 | 56,724 | 39,429 |
| – Equity holders of the parent5 | 979,857 | 1,179,703 |
| – Non-controlling interests6 | 56,724 | 39,429 |
Notes and alternative reported figures (6)
- “Total income” is an issuer-specific line, not mapped to a shared definition: Gross profit plus other income, as printed.
- “Net financing costs” is an issuer-specific line, not mapped to a shared definition: Finance income less finance costs, printed as a subtotal above its two components.
- “– Exchange differences on translating foreign subsidiaries” is an issuer-specific line, not mapped to a shared definition: OCI, items that may be subsequently reclassified.
- “– Non-controlling interests” is an issuer-specific line, not mapped to a shared definition: Attribution of profit for the year.
- “– Equity holders of the parent” is an issuer-specific line, not mapped to a shared definition: Attribution of total comprehensive income.
- “– Non-controlling interests” is an issuer-specific line, not mapped to a shared definition: Attribution of total comprehensive income.
Balance sheet
| Line (as printed) | FY to 28 Feb 2026Summary financial statements (summary)reported for the year | FY to 28 Feb 2025Summary financial statements (summary)comparative in FY to 28 Feb 2026 filingsource limitations |
|---|---|---|
| Non-current assets | 8,396,806 | 7,312,028 |
| Property, plant and equipment (including right-of-use assets)1 | 5,826,232 | 5,297,400 |
| Intangible assets | 1,740,823 | 1,448,057 |
| Investment in associate and joint ventures | 564,093 | 356,267 |
| Loans receivable2 | 117,275 | 72,804 |
| Deferred taxation | 148,383 | 137,500 |
| Current assets | 12,341,477 | 11,944,913 |
| Inventories | 7,908,461 | 7,905,213 |
| Trade and other receivables | 3,808,486 | 3,312,834 |
| Loans receivable3 | 78,395 | 115,169 |
| Taxation receivable | 46,379 | 26,343 |
| Cash and cash equivalents | 499,756 | 585,354 |
| Total assets | 20,738,283 | 19,256,941 |
| Equity and reserves4 | 5,644,770 | 5,218,221 |
| Share capital | 6,155,554 | 6,155,554 |
| Retained earnings | 4,179,169 | 3,722,968 |
| Other reserves | (4,689,953) | (4,660,301) |
| Non-controlling interest | 49,455 | 10,750 |
| Total equity | 5,694,225 | 5,228,971 |
| Non-current liabilities | 3,881,007 | 3,850,147 |
| Lease liability | 2,248,024 | 2,045,998 |
| Loans payable | 1,509,942 | 1,678,735 |
| Deferred taxation | 123,041 | 125,414 |
| Current liabilities | 11,163,051 | 10,177,823 |
| Trade and other payables | 7,910,598 | 7,246,228 |
| Lease liability | 695,209 | 617,851 |
| Loans payable | 517,636 | 575,124 |
| Employee-related obligations5 | 328,271 | 314,198 |
| Deferred revenue (contract liability) | 34,242 | 86,912 |
| Taxation payable | 10,375 | 19,873 |
| Bank overdraft | 1,666,720 | 1,317,637 |
| Total equity and liabilities | 20,738,283 | 19,256,941 |
Notes and alternative reported figures (5)
- “Property, plant and equipment (including right-of-use assets)”: mapping to a shared definition is uncertain. Printed as one line including right-of-use assets.
- “Loans receivable” is an issuer-specific line, not mapped to a shared definition: Non-current assets.
- “Loans receivable” is an issuer-specific line, not mapped to a shared definition: Current assets.
- “Equity and reserves”: mapping to a shared definition is uncertain. Printed 'Equity and reserves' as the subtotal of share capital, retained earnings and other reserves, before non-controlling interest.
- “Employee-related obligations” is an issuer-specific line, not mapped to a shared definition: Current liabilities.
Cash flow
| Line (as printed) | FY to 28 Feb 2026Summary financial statements (summary)reported for the year | FY to 28 Feb 2025Summary financial statements (summary)comparative in FY to 28 Feb 2026 filingsource limitations |
|---|---|---|
| Cash flow from operating activities | 1,792,711 | 904,696 |
| Cash inflow from trading operations1 | 3,124,134 | 3,222,535 |
| Movement in working capital2 | 125,820 | (923,746) |
| Finance income received | 28,492 | 24,060 |
| Finance costs paid3 | (559,644) | (515,516) |
| Taxation paid | (401,870) | (430,648) |
| Dividends paid4 | (524,221) | (471,989) |
| Cash flow from investing activities | (1,227,355) | (1,497,011) |
| - To maintain operations5 | (373,968) | (941,548) |
| - To expand operations6 | (729,620) | (460,596) |
| Proceeds on disposal of property, plant and equipment and intangible assets7 | 14,883 | 37,173 |
| Acquisition in business combination and subsidiaries, net of cash acquired8 | (23,475) | –9 |
| Acquisition of joint venture10 | (189,000) | (155,940) |
| Proceeds from joint ventures and associates11 | 29,353 | 28,101 |
| Advances paid on loans receivable12 | (7,076) | (4,201) |
| Receipt from loans receivable13 | 51,548 | –9 |
| Cash flow from financing activities | (994,577) | (174,637) |
| Bank loans repaid | (849,037) | (883,962) |
| Receipt of bank loans | 628,895 | 1,372,355 |
| Lease liability repayment | (691,992) | (641,172) |
| Purchase of treasury shares14 | (60,432) | (32,604) |
| Proceeds from non-controlling interest15 | –16 | 15,000 |
| Change in ownership interest in subsidiary17 | (22,011) | (4,254) |
| Net (decrease)/increase in cash and cash equivalents | (429,221) | (766,952) |
| Foreign currency implications on cash and cash equivalents | (5,460) | 1,441 |
| Cash and cash equivalents at beginning of year | (732,283) | 33,228 |
| Cash and cash equivalents at end of year | (1,166,964) | (732,283) |
- Printed “–”, read as nil: subtotal_arithmetic: cf.cash_from_investing.
- Printed “–”, read as nil: subtotal_arithmetic: cf.cash_from_financing.
Notes and alternative reported figures (15)
- “Cash inflow from trading operations” is an issuer-specific line, not mapped to a shared definition: Operating activities, before working capital.
- “Movement in working capital” is an issuer-specific line, not mapped to a shared definition: Operating activities.
- “Finance costs paid”: mapping to a shared definition is uncertain. Printed 'Finance costs paid' in operating activities; not split between borrowings and leases.
- “Dividends paid”: mapping to a shared definition is uncertain. Printed 'Dividends paid' within operating activities; not stated whether dividends to non-controlling interests are included.
- “- To maintain operations” is an issuer-specific line, not mapped to a shared definition: Investing activities.
- “- To expand operations” is an issuer-specific line, not mapped to a shared definition: Investing activities.
- “Proceeds on disposal of property, plant and equipment and intangible assets”: mapping to a shared definition is uncertain. Printed as one line for property, plant and equipment and intangible assets.
- “Acquisition in business combination and subsidiaries, net of cash acquired” is an issuer-specific line, not mapped to a shared definition: Investing activities; 2025 printed '–'.
- “Acquisition of joint venture” is an issuer-specific line, not mapped to a shared definition: Investing activities.
- “Proceeds from joint ventures and associates” is an issuer-specific line, not mapped to a shared definition: Investing activities.
- “Advances paid on loans receivable” is an issuer-specific line, not mapped to a shared definition: Investing activities.
- “Receipt from loans receivable” is an issuer-specific line, not mapped to a shared definition: Investing activities; 2025 printed '–'.
- “Purchase of treasury shares” is an issuer-specific line, not mapped to a shared definition: Financing activities.
- “Proceeds from non-controlling interest” is an issuer-specific line, not mapped to a shared definition: Financing activities; 2026 printed '–'.
- “Change in ownership interest in subsidiary” is an issuer-specific line, not mapped to a shared definition: Financing activities.
Segments
Segment data not yet collected for this company in the pilot.
Dividends
Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.
| Year ended | Event | Wording as printed | Amount | Unit | Source |
|---|---|---|---|---|---|
| 28 Feb 2026 | Dividends paid (cash flow statement) | Dividends paid |
(524,221) | ZAR thousands | Summary financial statements, p111 |
| 28 Feb 2025 | Dividends paid (cash flow statement) | Dividends paid |
(471,989) | ZAR thousands | Summary financial statements, p111 |
Sources
Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.
-
Dis-Chem Integrated Report 2026 for the financial year ended 28 February 2026 — Summary consolidated financial information
Year ended 28 February 2026 · Summary financial statements (summary) · final status not established
Audit: Forvis Mazars (named); no auditor's opinion on the full statements in this document
Final status: Published by the issuer inside its Integrated Report 2026. No auditor's report on the summary is printed. The report states that the Annual Financial Statements were audited by Forvis Mazars, who issued an unmodified audit opinion, and that the Integrated Annual Report itself is not subject to separate external assurance (PDF p4). The Board approved the Integrated Annual Report for release on 29 June 2026; the statement closes with the typeset names Larry Nestadt (Independent Non-Executive Chair) and Rui Morais (CEO), with no visible signatures (PDF p5, page image).
- Document date
- 29 Jun 2026
- Auditor's report
- date not recorded
- Board approval
- 29 Jun 2026
- Retrieved by us
- 8 Oct 2026 (not a publication date)
- Used for
- statement columns FY to 28 Feb 2026, FY to 28 Feb 2025
- Basis
- consolidated statements · ZAR thousands (printed “R’000”)
- Basic EPS 114.2 cents (2025: 137.6) and diluted EPS 114.1 cents (2025: 137.5) are printed separately (p108); basic mapped to eps_basic_diluted as ambiguous, diluted to a native per-share concept. Headline EPS from p112. Per-share figures are in cents and stored in rand with the printed figure and unit kept (minor_unit).
- Dividends paid and finance income received are presented within operating activities (p111). Cash and cash equivalents in the statement of cash flows are negative ((1 166 964); 2025: (732 283)): they equal cash and cash equivalents (499 756; 2025: 585 354) less the bank overdraft (1 666 720; 2025: 1 317 637) on the statement of financial position, a relation the summary does not print.
- No auditor's report on the summary is printed; the summary section states nothing about its source or assurance (pp108-114). Elsewhere the report states: 'The AFS have been audited by Forvis Mazars, who issued an unmodified audit opinion.' and 'While the IAR itself is not subject to separate external assurance, it has been reviewed by executive management, the Audit and Risk Committee and the Board' (p4).
- Consolidated statement of comprehensive income (p108), statement of financial position (p109), statement of changes in equity (p110), statement of cash flows (p111), earnings per share (p112) and segmental information (pp113-114); no accounting policies or other notes. Condensed lines: section subtotals are printed above their components; no total-liabilities line; additions to property, plant and equipment and intangible assets are printed only as 'to maintain' and 'to expand' operations.
Technical details
- File
- 132 pages, with a text layer
- SHA-256
158b9ed1415ade11589e04381be3b3680aca54313eeb27d8117d5474a3ceab8c- Entity as printed
- Dis-Chem Pharmacies Limited, Registration number 2005/009766/06, JSE share code: DCP, ISIN: ZAE000227831 (PDF p120)
- Issuer copy
- retrieved 2026-10-08T18:51:22Z
Data notes
No figure-level notes beyond those in the tables.
Review status: every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Independent review is pending for every figure; automated checks and the AI-assisted verification are not independent review.
Download
Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.
South Africa country page · Company methodology and coverage